Alkem Laboratories

ALKEM.NS

Mumbai, India· Est. 1973

alkemlabs.com

Is this your company? Claim your profile to update info and connect with investors.

Claim profile

ALKEM.NS · Stock Price

INR 5,590.50+651.00 (+13.18%)

Market Cap: $7.1B

Historical price data

Market Cap: $7.1BPipeline: 3 drugs (1 Phase 3)Patents: 4Founded: 1973Employees: 10,000+HQ: Mumbai, India

Sector Ranking#17 in Small Molecule Drugs

Overview

Founded in 1973, Alkem Laboratories has grown from a domestic manufacturer into a globally recognized pharmaceutical company with a mission to deliver trusted, affordable healthcare through innovation and quality. Its strategic pillars include a deep focus on complex generics and novel drug delivery systems, a sprawling international footprint, and a diversified portfolio across key therapeutic areas like anti-infectives, cardiology, and gastroenterology. The company's success is underpinned by its aggressive patent challenge strategy in regulated markets like the US, a vast network of 18 manufacturing facilities, and a strong commercial engine driving growth in both emerging and developed markets.

CardiologyAnti-infectiveGastroenterologyPain ManagementNutraceuticals

Technology Platform

Specialized in complex generic formulations and advanced Novel Drug Delivery Systems (NDDS), including transdermal delivery and oral films, supported by vertical integration through in-house API manufacturing.

Pipeline

3 drugs in pipeline1 in Phase 3

Drug	Indication	Stage
ENZ215 + Prolia	Postmenopausal Osteoporosis	Phase 3
BSG005	Invasive Fungal Infection	Phase 1/2
ENZ215 + EU Sourced Prolia + US Sourced Prolia	Healthy Male Subjects	Phase 1

Funding History

IPOUndisclosedUndisclosedDec 21, 2015

Opportunities

Significant opportunities exist in the US market through first-to-file generic exclusivities on complex products and biosimilars.

High-growth emerging markets like the Philippines and others in ASEAN present avenues for volume-led expansion with tailored portfolios.

The global trend of API supply chain diversification also benefits its vertical integration model.

Risk Factors

Key risks include regulatory compliance across its extensive manufacturing network, intense price erosion in the US generics market, and potential litigation losses from aggressive patent challenges.

Geopolitical and currency volatility in its many international markets also pose operational and financial risks.

Competitive Landscape

Alkem competes with large Indian pharma peers (Sun Pharma, Dr. Reddy's, Cipla) domestically and globally, and with multinational generic firms (Teva, Viatris) in regulated markets. Its competitive edge lies in complex generics capabilities, vertical integration, and a strong balance sheet for sustained investment.